SUPN
Supernus Pharmaceuticals Inc.
$47.77
-$0.44(-0.91%)
43
Overall
40
Value
30
Tech
60
Quality
Market Cap
$2.81B
Volume
474.84K
52W Range
$30.83 - $59.68
Target Price
$62.83
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $215.0M | $302.2M | $408.9M | $392.8M | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M | ||
| Total Revenue | $210.1M | $302.2M | $408.9M | $392.8M | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-12.0M | $-15.2M | $-15.4M | $16.7M | $52.5M | $75.1M | $87.2M | $83.8M | $77.9M | $74.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $203.0M | $287.0M | $393.5M | $376.1M | $467.9M | $504.7M | $580.0M | $523.7M | $583.9M | $644.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $148.8M | $187.5M | $249.1M | $227.5M | $292.3M | $425.2M | $534.4M | $510.3M | $508.4M | $681.3M | ||
| Research & Development | $42.8M | $49.6M | $89.2M | $69.1M | $76.0M | $90.5M | $74.6M | $91.6M | $108.8M | $106.2M | ||
| Research Expense | $42.8M | $49.6M | $89.2M | $69.1M | $76.0M | $90.5M | $74.6M | $91.6M | $108.8M | $106.2M | ||
| Selling, General & Administrative | $106.0M | $137.9M | $159.9M | $153.2M | $200.7M | $304.8M | $377.2M | $336.4M | $321.6M | $485.6M | ||
| Selling & Marketing Expenses | $106.0M | $137.9M | $159.9M | $40.8M | $54.5M | $86.0M | $131.7M | $99.7M | $88.5M | -- | ||
| General & Administrative Expenses | $-2.7M | $-2.7M | $-3.6M | $153.2M | $200.7M | $304.8M | $377.2M | $336.4M | $321.6M | $485.6M | ||
| Promotion & Advertising | -- | -- | -- | $40.8M | $54.5M | $86.0M | $131.7M | -- | -- | -- | ||
| Salaries & Wages | $-5.9M | $-8.4M | $-11.3M | -- | -- | $146.4K | $17.6M | -- | -- | -- | ||
| Depreciation & Amortization | $-1.1M | $-1.2M | $-1.9M | $5.2M | $15.7M | $30.0M | $82.6M | $82.4M | $78.0M | $89.5M | ||
| Depreciation & Amortization | $-1.1M | $-1.2M | $-1.9M | $5.2M | $15.7M | $30.0M | $82.6M | $82.4M | $78.0M | $89.5M | ||
| Amortization | $-1.6M | $-6.9M | $-17.0M | $5.2M | $15.7M | $30.0M | $82.6M | $82.4M | $78.0M | $89.5M | ||
| Other Operating Expenses | $-662.0K | $-1.2M | $-1.1M | $-208.0K | $-1.0M | $-898.0K | $-32.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $54.2M | $99.5M | $144.4M | $148.6M | $173.7M | $86.0M | $46.1M | $-5.3M | $81.7M | $-62.3M | ||
| EBITDA | $53.6M | $108.9M | $145.2M | $169.8M | $210.5M | $146.7M | $150.9M | $90.6M | $183.7M | $50.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $543.0K | $134.0K | $-13.8M | $18.2M | $23.8M | $23.4M | $2.5M | $2.4M | -- | -- | ||
| Interest Income Operating | $543.0K | $134.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $-3.1M | $1.4M | $13.8M | $21.6M | $18.7M | -- | $3.6M | -- | $16.2M | -- | ||
| Net Non-Operating Interest Income/Expense | $-3.6M | $1.3M | $27.7M | $21.3M | $16.0M | $8.8M | $1.0M | $-1.3M | $16.2M | -- | ||
| Gain on Sale of Securities | $448.0K | $76.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $223.0K | $219.0K | $4.3M | $1.1M | $7.0M | $6.3M | $-15.1M | $8.2M | $-22.3M | $12.2M | ||
| Other Special Charges | $-671.0K | $-295.0K | $-4.3M | $-1.1M | $-5.0M | $-12.9M | $14.6M | $10.5M | $16.2M | $13.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | $14.2M | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $20.2M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $50.9M | $100.8M | $126.3M | $147.5M | $192.4M | $96.6M | $63.3M | $5.2M | $97.9M | $-49.0M | ||
| Pre-Tax Income | $50.4M | $100.6M | $140.2M | $147.5M | $168.6M | $73.2M | $60.7M | $2.8M | $97.9M | $-49.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-40.9M | $43.3M | $29.2M | $34.4M | $41.7M | $19.8M | $32.0K | $1.5M | $24.0M | $-10.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $91.2M | $57.3M | $111.0M | $113.1M | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | $-38.5M | ||
| Net Income (Continuing Operations) | $91.2M | $57.3M | $111.0M | $113.1M | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | $-38.5M | ||
| Net Income (Discontinued Operations) | $91.2M | $57.3M | $111.0M | $113.1M | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | $-38.5M | ||
| Net Income (Common Stockholders) | $91.2M | $57.3M | $111.0M | $113.1M | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | $-38.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $136.8M | $172.3M | $233.7M | $244.2M | $344.8M | $500.3M | $621.6M | $594.1M | $586.3M | $755.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $49.5M | $50.8M | $52.0M | $52.4M | $52.6M | $53.1M | $53.7M | $54.5M | $55.1M | $56.5M | ||
| Average Shares Outstanding (Diluted) | $51.7M | $53.3M | $54.1M | $53.8M | $53.7M | $54.4M | $61.7M | $55.5M | $56.0M | $56.5M | ||
| Shares Outstanding | $50.2M | $51.5M | $52.3M | $52.5M | $52.9M | $53.4M | $54.4M | $54.7M | $55.8M | $57.6M | ||
| Basic EPS | $1.84 | $1.13 | $2.13 | $2.16 | $2.41 | $1.01 | $1.13 | $0.02 | $1.34 | $-0.68 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $2.16 | $2.41 | $1.01 | $1.13 | $0.02 | $1.34 | $-0.68 | ||
| Diluted EPS | $1.76 | $1.08 | $2.05 | $2.1 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | $-0.68 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $2.1 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | $-0.68 | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | $12.9M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | $12.9M | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | $-2.5M | -- | -- | -- | ||
| Other Gand A | $-2.7M | $-2.7M | $-3.6M | $153.2M | $200.7M | $304.8M | $377.2M | $336.4M | $321.6M | $485.6M | ||
| Rent And Landing Fees | $-2.7M | $-2.7M | $-3.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $106.0M | $137.9M | $159.9M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SUPN | $47.77 | -0.9% | 474.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Supernus Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW